

→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 10



Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CSN ↓	340	2002/0162129 A1	10-31-2002	Lannfelt	
	326	2002/0136718 A1	09-26-2002	Raso	
	325	2001/0102261 A1	08-01-2002	Raso	
	306	6,417,178 B1	07-09-2002	Klunk et al.	
	342	2002/0009445 A1	01-24-2002	Du et al.	
	267	6,294,171 B2	09-25-2001	McMichael	
	234	6,284,221 B1	09-04-2001	Schenk, et al.	
	300	2001/0018053 A1	08-30-2001	McMichael	
	230	6,262,335 B1	07-17-2001	Hsiao et al.	
	345	2002/0077288 A1	06-21-2001	Frangione	
	231	6,114,133	09-05-2000	Seubert et al.	
	221	5,989,566	11-23-1999	Cobb et al.	
	346	5,935,927	08-10-1999	Vitek et al.	
	321	5,837,672	11-17-1998	Schenk et al.	
	353	5,824,322	10-20-1998	Balasubramanian	
	357	5,776,468 B1	07-07-1998	Hauser et al.	
	356	5,622,701	04-22-1997	Berg	
	320	5,593,846	01-14-1997	Schenk et al.	
	358	5,583,112 B2	12-10-1996	Kensil et al.	
	GB	284	5,231,170	07-27-1993	Averback

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	296	60/254,465	12-08-2000	Holtzman et al.	
	297	60/254,498	12-08-2000	Holtzman et al.	
	305	09/724,842	11-28-2000	Chalifour et al.	
	295	60/184,601	02-24-2000	Holtzman et al.	
	282	60/169,687	12-08-1999	Chain	
	242	60/168,594	11-29-1999	Chalifour et al.	
	283	09/441,140	11-16-1999	Solomon et al.	
		299	60/186,295	03-01-2000	Rasmussen et al.

Examiner
SignatureDate
Considered

2/23/2004

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231
PA 3307758 v1



→

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
CWN	352	WO	02/34777	A1	05-02-2002			
	351	WO	02/34878	A2	05-02-2002			
	343	EP	1 172 378	A1	01-16-2002			
	344	WO	01/90182	A2	11-29-2001			
	348	WO	01/77167	A2	10-18-2001			
	294	WO	01/62801	A2	08-30-2001			
	298	WO	01/42306	A2	06-14-2001			
	243	WO	01/39796	A2	06-07-2001			
	341	WO	02/03911	A2	04-07-2001			
	324	WO	00/72870	A1	12-07-2000			
	323	WO	00/72876	A2, A3	12-07-2000			
	322	WO	00/72880	A2, A3	12-07-2000			
	240	WO	00/43039	A1	07-27-2000			
	301	WO	01/62284	A2	03-01-2000			
	331	WO	99/06545	A2	11-02-1999			
V	187	EP	783 104	A1	07-09-1997			
	227	WO	95/11008	A2	04-27-1995			

Examiner
SignatureDate
Considered

2/23/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
PA 3307758 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Applicati n Number	09/724,953
		Filing Dat	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	15270J-005913US

Sheet	3	of	10
-------	---	----	----

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CSO	290	YOUNKIN, "Amyloid β vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).	—
	292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid β protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).	—
	275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).	—
	223	WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)	—
	274	WEINER et al., "Nasal administration of amyloid- β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000).	—
	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <u>DNA Cell Biol.</u> (11):713 21 (2001).	—
	276	TJERNBERG et al., "Arrest of β -amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996).	—
	273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <u>Curr. Op. in Chem. Biology</u> , 4:377-382 (2000).	—
	339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <u>PNAS</u> , 92:4299-4303 (1995).	—
	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid β -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996).	—
SN	338	STEIN and JOHNSON, "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <u>The Journal of Neuroscience</u> , 22(17):7380-7388 (September 1, 2002).	—

CONSIDERED DO NOT PRINT (NO DATE).

Examiner Signature		Date Considered	2/23/04
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1999).
316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <u>Nat Med</u> . 4(7):822-6 (1998).
319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci</u> . 2(8):595-8 (2001).
337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech</u> , 18(1):34-39 (2000).
315	SINHA, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. <u>Ann N Y Acad Sci</u> . 920:206-8 (2000).
314	SIGURDSSON, et al. In vivo reversal of amyloid-beta lesions in rat brain. <u>J Neuropathol Exp Neurol</u> . 59(1):11-17 (2000).
330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol</u> , 20:1425-1429 (2000).
313	SELKOE, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. <u>Trends Cell Biol</u> . 8(11):447-53 (1998).
270	SCHENK, et al., " β -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).
312	SCHENK, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. <u>DNA Cell Biol</u> . 20(11):679-81 (2001).
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).
278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- β -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).
279	SAITO et al., "Vector-mediated delivery of 125 I-labeled β -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A β^{1-40} vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).
304	RAGO, V.A., Grant application # 1 R43 AG15746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).

CONSIDERED; DO NOT PRINT (NO DATE).

Examiner
Signature

[Signature]

Date
Considered

2/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307758 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

GW	269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).	
	232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).	
	336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	
	280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).	
	329	NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic Research</u> 7:73-75 (1998).	
	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	
	235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acta</u> , 104:480-486 (1965).	
	281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).	
	268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid β protein (A β) subtypes (A β 40 and A β 42/43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995).	
	250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995).	
	354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, <u>medpharm</u> Scientific Publishers, Stuttgart, Germany.	
	355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.	
✓	359	MUNCH et al., "Potential neurotoxic inflammatory response to A β vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.	
GW	233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989).	

Examiner
SignatureDate
Considered

2/23/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000).
310	MERLUZZI, et al. Humanized antibodies as potential drugs for therapeutic use. <u>Adv Clin Path.</u> 4(2):77-85 (2000).
265	MENA, et al., "Monitoring pathological assembly of tau and β -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).
238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998).
264	MCGEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).
309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997).
335	MASLIAH et al., " β -Amyloid peptides enhance α -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995).
263	MANN, et al., "Amyloid β protein ($A\beta$) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42(43)}$," <u>Annals of Neurology</u> , 40:149-156 (1996).
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).
260	LEMERE, et al., "Nasal $A\beta$ treatment induces anti- $A\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997).
258	KIDA, et al., "Early amyloid- β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).

Examiner
SignatureDate
Considered

2/23/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/724,953		
		Filing Date	November 28, 2000		
		First Named Inventor	Dale B. Schenk		
		Art Unit	1647		
		Examiner Name	Christopher Nichols		
Sheet	7	of	10	Attorney Docket Number	15270J-005913US

347	JORBECK et al., "Artificial <i>Salmonella</i> Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <i>Infection and Immunity</i> , May:497-502 (1981).	
334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <i>Molecular Microbiology</i> , 5(7):1755-1767 (1991).	
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <i>Brain Research Protocols</i> , 2:23-30 (1997).	
308	JANUS, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. <i>Nature</i> . 408(6815):979-82 (2000).	
256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <i>Lab. Invest.</i> , 57:446-449 (1987).	
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).	
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2", <i>Immunology</i> , Vol. 78: 643-649 (1993).	
255	HARIGAYA, et al., "Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 211:1015-1022 (1995).	
241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992).	
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with β -amyloid: could T-cell activation have a harmful effect?", <i>TINS</i> , 23:114 (2000).	
237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 93:149-153 (1998).	
253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>Journal of Biological Chem.</i> , 273:29719-29726 (1998).	

Examiner Signature		Date Considered	2/23/04
--------------------	--	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3307758 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Applicati n Numb r	09/724,953
Filing Dat	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

252	GEDDES, "N-terminus truncated β -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).	—
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990).	—
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	—
244	FRENKEL, et al., "Modulation of Alzheimer's β -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000).	—
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's β -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).	—
247	FRENKEL et al., "Immunization against Alzheimer's β -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).	—
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β -amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999).	—
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	—
328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of B-Amyloid Precursor Protein Processing," <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	—
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends In Pharm. Sci.</u> , 22:2-3 (2001).	—
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	—
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	—
288	DUMERY et al., " β -Amyloid protein aggregation: Its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).	—

Examiner
SignatureDate
Considered

2/23/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/724,953
		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher Nichols
Sheet 9 of 10	Attorney Docket Number	15270J-005913US	

CSW	318	DU, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. <u>Neurology</u> . 57(5):801-5 (2001).	1
	220	Dialog/Derwent, Abstract of WPI Acc No. 1997-054436/199706. Stable vaccine compns. comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water sol. organic solvent and saline or water, Derwent File 351. Derwent WPI database. (Publication date unknown.)	
	293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).	1
	287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).	1
	286	CORDELL, B., " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).	1
	333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both α -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000)	1
	291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).	1
	302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid β -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).	1
	307	CHEN et al., A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. <u>Nature</u> . 408(6815):975-9 (2000).	1
	332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V \rightarrow F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds, 117:327-337 (1998).	1
	222	Chemical Abstract Database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)	
✓	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	1
CSW	266	CHAPMAN, PAUL F., "Model behavior," <u>Nature</u> , 408:915-916 (2000).	1

CONSIDERED, DO NOT PRINT (NO DATE)

Examiner Signature		Date Considered	2/23/04
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/724,953
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 28, 2000
		First Named Inventor	Dale B. Schenk
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	15270J-005913US
Sheet	10	of	10

GN	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : http://www.fda.gov/cber/vaccine/thimerosal.htm , last updated May 16, 2002.	—
I	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992).	—
↓	327	CAMERON, "Recent Advances in Transgenic Technology," <i>Molecular Biotechnology</i> , 7:253-265 (1997).	—
✓	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	—
GN	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 225(4): 1075-1093 (1992).	—

Examiner Signature		Date Considered	2/23/04
-----------------------	--	--------------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3307758 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Dale B. Schenk
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	15270J-005913US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

2/23/01

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

PA 3307744 v1



→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/724,953
				Filing Date	November 28, 2000
				First Named Inventor	Dale B. Schenk
				Art Unit	1647
				Examiner Name	Christopher Nichols
Sheet	2	of	2	Attorney Docket Number	15270J-005913US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	
	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	

Examiner Signature		Date Considered	2/23/04
--------------------	--	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3307744 v1

+

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known

Application Number 09/585,817
Filing Date June 1, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 1646-1647
Examiner Name Unassigned Nichols
Attorney Docket Number 15270J-005910US

RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known

Application Number 09/585,817
Filing Date June 1, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 1646-1647
Examiner Name Unassigned Nichols
Attorney Docket Number 15270J-005910US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					
	AS					

Examiner
Signature

Date
Considered

2/23/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3172864 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/585,817
Filing Date	June 1, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1646-1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005910US

Sheet 3 of



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC		
	BD		
	BE		
	BF		
	BG		
	BH		
	BI		
	BJ		
	BK		
	BL		
	BM		

Examiner Signature		Date Considered	2/23/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3172864 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005913US

U.S. PATENT DOCUMENTS

U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
196	6,150,091	Pandolfo et al.	11-21-2000	
1	6,057,367	Stamler et al.	05-02-2000	
2	5,958,883	Snow	09-28-1999	
3	5,955,317	Suzuki et al.	09-21-1999	
4	5,955,079	Mond et al.	09-21-1999	
5	5,877,399	Hsiao et al.	03-02-1999	
6	5,869,093	Weiner et al.	02-09-1999	
7	5,869,054	Weiner et al.	02-09-1999	
8	5,854,204	Findeis et al.	12-29-1998	
9	5,851,998	Kline	12-22-1998	
10	5,849,298	Weiner et al.	12-15-1998	
11	5,837,473	Maggio et al.	11-17-1998	
12	5,786,180	Konig et al.	07-28-1998	
207	5,780,587	Potter	07-14-1998	
13	5,753,624	McMichael et al.	05-19-1998	
14	5,750,349	Suzuki et al.	05-12-1998	
197	5,744,368	Goldgaber et al.	04-28-1998	
211	5,736,142	Settle et al.	04-07-1998	
15	5,733,547	Weiner et al.	03-31-1998	
16	5,688,651	Solomon	11-18-1997	
17	5,679,348	Nesbun et al.	10-21-1997	
18	5,645,820	Hafler et al.	07-08-1997	
19	5,641,474	Hafler et al.	08-24-1997	
20	5,641,473	Hafler et al.	08-24-1997	
21	5,612,486	McConlogue et al.	03-18-1997	
22	5,605,811	Seubert et al.	02-25-1997	
23	5,585,100	Mond et al.	12-17-1996	
24	5,571,500	Hafler et al.	11-05-1996	
25	5,571,499	Hafler et al.	11-05-1996	
175	5,441,870	Seubert, et al.	08-15-1995	
26	5,434,170	Andrulis, Jr.	07-18-1995	
27	5,387,742	Cordell	02-07-1995	
181	5,270,165	Van Nostrand et al.	12-14-1993	
28	5,231,000	Majocho et al.	07-27-1993	
29	5,220,013	Ponte et al.	06-15-1993	
30	5,208,036	Eppstein et al.	05-04-1993	
31	5,192,753	McGeer et al.	03-09-1993	

Examiner
Signature

G. Michael

Date

Considered

11/15/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

OCT 05 2001

RECEIVED

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005913US

32	5,187,153	—	Cordell et al.	02-16-93	—
33	5,057,540	—	Kensil et al.	10-15-1991	—
198	5,004,697	—	Pardridge	04-0201991	—
34	4,686,829	—	Glenner et al.	05-18-1987	—

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
8/3	35	EP	911 038	A2	—	04-28-1999	—	—
8/3	36	EP	868 918	A2	—	10-07-1998	—	—
8/3	37	EP	863 211	A1	—	09-09-1998	—	—
8/3	38	EP	845 270	A1	—	06-03-1998	—	—
8/3	39	EP	782 859	A1	—	07-09-1997	—	—
8/3	40	EP	683 234	A1	—	11-22-1995	—	—
8/3	41	EP	666 080	A1	—	08-09-1995	—	—
8/3	42	EP	652 962	B1	—	12-16-1998	—	—
8/3	43	EP	639 081	B1	—	11-03-1999	—	—
8/3	44	EP	613 007	A2	—	08-31-1994	—	—
8/3	45	EP	594 607	B1	—	08-27-1997	—	—
8/3	46	EP	561 087	B1	—	08-04-1999	—	—
8/3	47	EP	526 511	B1	—	05-28-1997	—	—
8/3	48	EP	506 785	B1	—	03-15-2000	—	—
8/3	49	EP	451 700	A1	—	10-18-1991	—	—
8/3	50	EP	440 619	B1	—	01-24-1996	—	—
8/3	51	EP	359 783	B1	—	11-29-1995	—	—
8/3	52	EP	276 723	B1	—	12-08-1993	—	Yes
8/3	187	EP	783 404	A1	—	07-09-1997	—	—
8/3	199	PCT	00/77178	A1	—	12-21-2000	—	—
8/3	188	PCT	00/43049	A1	—	07-27-2000	—	—
8/3	53	PCT	99/60024	A1	—	11-25-1999	—	—
8/3	54	PCT	99/60021	A2	—	11-15-1999	—	—
8/3	55	PCT	99/58564	A1	—	11-18-1999	—	—
8/3	56	PCT	99/06066	A2	—	02-11-1999	—	—
8/3	57	PCT	99/27949	A1	—	06-10-1999	—	—
8/3	58	PCT	99/27944	A1	—	06-10-1999	—	—
8/3	59	PCT	99/27911	A1	—	06-10-1999	—	—
8/3	203	PCT	99/00150	A2	—	01-07-1999	—	—
8/3	60	PCT	98/44955	A1	—	10-15-1998	—	—
8/3	61	PCT	98/07850	A2	—	02-28-1998	—	—

Examiner
Signature

G. Nichols

Date
Considered

11/15/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173244 v1

RECEIVED
OCT 05 2001

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 10

Complete if Known

Application Number 09/724,953
Filing Date November 28, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 1647
Examiner Name Unassigned Nichols
Attorney Docket Number 15270J-005913US

OCT 0 5 2001

RECEIVED

TECH CENTER 1600/2900

202	PCT	97/21728	A1		06-19-1997	
62	PCT	97/17613	A1		05-15-1997	
63	PCT	96/39176	A1		12-12-1996	
208	PCT	96/28471	A1		09-19-1996	
64	PCT	96/25435	A1		08-22-1996	
65	PCT	96/18900	A1		06-20-1996	
66	PCT	95/31996	A1		11-30-1995	
200	PCT	95/12815	A1		05-11-1995	
67	PCT	95/11994	A1		05-04-1995	
68	PCT	95/11311	A1		04-27-1995	
69	PCT	95/05853	A1		03-02-1995	
70	PCT	95/04151	A2		02-09-1995	
201	PCT	94/28412	A1		12-08-1994	
71	PCT	94/03615	A1		02-17-1994	
72	PCT	94/01772	A1		01-20-1994	
73	PCT	93/21950	A1		11-11-1993	
74	PCT	93/16724	A1		09-02-1993	
75	PCT	93/15760	A1		08-19-1993	
76	PCT	93/14200	A1		07-22-1993	
205	PCT	93/04194	A1		03-04-1993	
77	PCT	93/02189	A1		02-04-1993	
78	PCT	92/13069	A1		08-06-1992	
79	PCT	92/06708	A1		04-30-1992	
80	PCT	92/06187	A1		04-16-1992	
81	PCT	91/19810	A1		12-26-1991	
82	PCT	91/16819	A1		11-14-1991	
83	PCT	91/12816	A1		09-05-1991	
84	PCT	91/08760	A1		06-27-1991	
85	PCT	90/12871	A1		11-01-1990	
86	PCT	90/12870	A1		11-01-1990	
87	PCT	89/01343	A1		02-23-1989	
88	PCT	89/06242	A1		07-13-1989	
89	PCT	89/06689	A1		07-27-1989	
90	PCT	89/03687	A1		05-05-1989	
91	PCT	88/10120	A1		12-29-1988	
92	GB	2 220 211	A		01-04-1990	
93	GB	2 335 192	A		09-15-1999	

Examiner
Signature

[Handwritten Signature]

Date
Considered

11/15/02

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173244 v1

+

1

五

五

CE

FIN

五

160

2100

100

1

F

At the end of the day

11/15/02

OCT 05 200

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,953
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1647
		Examiner Name	Unassigned Nichols
Sheet 5 of 10	Attorney Docket Number	15270J-005913US	

TECH CENTER 1600/2900

OCT 05 2001

RECEIVED



104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neuro. Sciences</u> , 59:341-347 (1983).	
105	FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).	
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).	
210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).	
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).	
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).	
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).	
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 651 (1998).	
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	
114	GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-708 (1991).	
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).	
190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	
118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	

Examiner Signature		Date Considered	11/15/02
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173244 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,953
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1647
		Examiner Name	Unassigned Nichols
		Attorney Docket Number	15270J-005913US
Sheet	6	of	10

TECH CENTER 1600/2900

OCT 0 5 2001

RECEIVED

119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 87-119 (1997).	1
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	1
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1998).	1
193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	1
177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	1
122	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	1
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	1
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	1
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	1
192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994).	1
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	1
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-378 (1991).	1
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	1
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	1
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	1
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the A β 4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	1
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	1
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	1

Examiner Signature		Date Considered	11/15/02
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173244 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005913US

TECH CENTER 1600/2900

OCT 0 5 2001

RECEIVED

131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).	
132	LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part I, Abstract 519.8, 29th Annual Meeting, (October 23-28, 1999).	
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).	
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).	
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).	
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).	
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).	
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).	
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).	
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86408t (1994).	
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	
144	RASS, V.A., Grant application # 1-FH8 AG15746-01, (publication date unknown)	

Examiner
Signature

Julia D.

Date

Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 10

Complete if Known

Application Number 09/724,953
Filing Date November 28, 2000
First Named Inventor Schenk, Dale B.
Group Art Unit 1647
Examiner Name Unassigned Nichols
Attorney Docket Number 15270J-005913US

TECH CENTER 1600/2900

OCT 05 2001

RECEIVED

145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	
148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	
151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	

Examiner
Signature

Date
Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3173244 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 10

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005913US

OCT 0 5 2001

RECEIVED

TECH CENTER 1600/2900

159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	1
160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	1
161	SOLOMON, A., "Pro-Peptide (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).	1
162	SOLOMON, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown).	1
182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	1
184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	1
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	1
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of <i>in vitro</i> aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	1
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	1
183	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).	1
184	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	1
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).	1
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	1
167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).	1
168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	1
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	1
180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	1
170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).	1

Examiner Signature		Date Considered	11/15/02
--------------------	--	-----------------	----------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3173244 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 10

TRADEMARK

Complete if Known

Application Number	09/724,953
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	Unassigned Nichols
Attorney Docket Number	15270J-005913US

CDU	171	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	1
CDU	172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-874 (2000).	1
CDU	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).	1
CDU	173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).	1
CDU	174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	1

CONSIDERED; DO NOT PRINT (NO DATE)

Examiner
Signature

G. M. H. S.

Date
Considered

11/15/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3173244 v1

OCT 05 2001

RECEIVED

TECH CENTER 1600/2900

Dale B. Schenk
Application No.: 09/585,817
Page 2



PATENT

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AT					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AU							
	AV							
	AW							
	AX							
	AY							
	AZ							
	BA							
	BB							

Examiner Signature		Date Considered	2/3/04
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231
PA 3172864 v1